Sucampo Receives $20 Million From Takeda for Milestone

Sucampo Pharmaceuticals (Sucampo), a leader in functional fatty acid research and development, announced that it received $20 million from its business partner, Takeda Pharmaceutical Company (Takeda), as payment for achieving a development milestone -- initiation of a Phase III clinical trial of lubiprostone to treat patients with constipation-predominant irritable bowel syndrome (IBS-C). Lubiprosotone, one of the Sucampo's proprietary agents, is a new class of functional fatty acid that produces chloride channel-opening activity.

DrugNewswire (http://www.drugnewswire.com/670/)